Answers are grounded in this paper and cite their sources.
Demonstrates improved antileukemic efficacy in mice by using Bifidobacterium pseudolongum with arsenic trioxide, suggesting a novel treatment strategy.
BP is an effective adjunct to ATO therapy, counteracting gut dysbiosis, intestinal damage, and the immune microenvironment while synergistically improving antileukemic efficacy. Targeting the gut-leukemia axis with BP represents a promising strategy for improving the precision and safety of APL treatment.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: